Graft vs Host Disease: Novel Management Strategies for a Chronic Condition
Released On
June 16, 2023
Expires On
June 16, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Oncology, Hematology/Oncology, Transplant Specialists
Topic(s)
Graft-Versus-Host Disease (cGVHD)
This activity is provided by Med Learning Group.
This activity is co-provided by AMEDCO
Nursing learners, view this Learner Notification prior to starting this activity
This activity is supported by an educational grant from Sanofi US.
Credit Available
- Physicians — maximum of 1.0AMA PRA Category 1 Credit™
- Nurses — 1.0 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
The intended audience for this activity is transplant specialists, oncologists, hematologists, and other healthcare professionals involved in the treatment of patients with GVHD.
Program Overview
This enduring activity takes learners on a compelling journey in managing chronic graft-versus-host disease (cGVHD) by explaining the evidence-based diagnostic criteria for cGVHD for prompt diagnosis; discussing the clinical safety and efficacy data of recently approved and investigational therapeutic agents, and finally, developing strategies to create treatment plans that address the psychosocial impact of disease and prioritize improvement in quality of life. Learners are invited to explore challenging aspects of this condition with the goal of informing selection of the most appropriate treatment regimens targeting disease etiopathogenesis. This immersive experience highlights the importance of early recognition in the effective management of cGVHD.
Learning Objectives
After completing the CME activity, learners should be better able to:
- Explain the evidence-based diagnostic criteria for chronic GVHD for prompt diagnosis
- Discuss the clinical safety and efficacy data of recently approved and investigational therapeutic agents
- Develop strategies to create treatment plans that include considerations for improvements in quality of life and psychosocial impact of disease
Faculty
Corey S. Cutler, MD, MPH, FRCPC
Director, Adult Stem Cell Transplantation Program
Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School
Boston, Massachusetts
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
Physician Credit Designation Statement
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Continuing Education Credit Designation
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
Disclosure Policy Statement
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosure of Relevant Financial Relationship(s)
- Dr. Cutler
- Consulting Fees : Omeros, CareDX, Mallinckrodt, Editas Medicine, Deciphera, Jazz, Incyte, Sanofi, Janssen, Bristol Myers Squibb, CTI BioPharma, Equillium, Jasper Therapeutics and CSL Behring
- Ownership: Cimeio Therapeutics and Oxford Immune Algorithmics
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Tara Mayfield, Medical Director of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Jessica Feygin, Program Coordinator of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Daniel DaSilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
Method of Participation
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures
- Participate in the enduring activity
- Complete pre-and-post surveys and evaluation
You will receive your certificate as a downloadable file.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.
Disclaimer
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: https://www.medlearninggroup.com/privacy.
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com.
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
